On December 1, 2025, Simcere Pharmaceutical Group Limited (Stock code: 2096) approved the grant of a total of 15,408,100 restricted share units (RSUs) to 97 eligible participants under its 2021 RSU Scheme, at nil consideration. These RSUs will be satisfied through shares previously granted but subsequently lapsed in accordance with the rules of the scheme.

Among the recipients are executive directors and senior management personnel. In particular, 2,100,000 RSUs were granted to an executive director, with an additional 240,000 RSUs granted to another. Three senior managers received a combined total of 2,730,000 RSUs, and the remaining 10,338,100 RSUs were allocated to 92 other employees. Each RSU represents one underlying share.

These awards are subject to a performance-based vesting schedule spread over three years, commencing on December 1, 2026, and include a clawback mechanism that applies in the event of material breaches of obligations or ethical concerns. The closing price of the shares on the grant date was HK$13.93 per share. Following this grant, 241,177,711 shares remain available under the existing scheme mandate. The grant to certain executive directors was approved by all independent non-executive directors. The company has confirmed that no financial assistance will be provided to facilitate the acquisition of the shares under the scheme.